Abstract
Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 449-455 |
| Number of pages | 7 |
| Journal | Korean Journal of Internal Medicine |
| Volume | 28 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2013 Jul 1 |
Fingerprint
Keywords
- Chemoradiotherapy
- Limited-stage
- Small cell lung carcinoma
- Start of any treatment until the end of radiotherapy
ASJC Scopus subject areas
- Internal Medicine
Cite this
The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer. / Lee, Kyoung Ju; Lee, Eun Joo; Hur, Gyu Young; Lee, Sang Yeub; Kim, Je Hyeong; Shin, Chol; Shim, Jae Jeong; In, Kwang Ho; Kang, Kyung Ho; Yoo, Se Hwa; Lee, Sung Yong.
In: Korean Journal of Internal Medicine, Vol. 28, No. 4, 01.07.2013, p. 449-455.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer
AU - Lee, Kyoung Ju
AU - Lee, Eun Joo
AU - Hur, Gyu Young
AU - Lee, Sang Yeub
AU - Kim, Je Hyeong
AU - Shin, Chol
AU - Shim, Jae Jeong
AU - In, Kwang Ho
AU - Kang, Kyung Ho
AU - Yoo, Se Hwa
AU - Lee, Sung Yong
PY - 2013/7/1
Y1 - 2013/7/1
N2 - Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
AB - Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
KW - Chemoradiotherapy
KW - Limited-stage
KW - Small cell lung carcinoma
KW - Start of any treatment until the end of radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84880422687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880422687&partnerID=8YFLogxK
U2 - 10.3904/kjim.2013.28.4.449
DO - 10.3904/kjim.2013.28.4.449
M3 - Article
C2 - 23864803
AN - SCOPUS:84880422687
VL - 28
SP - 449
EP - 455
JO - Korean Journal of Internal Medicine
JF - Korean Journal of Internal Medicine
SN - 0494-4712
IS - 4
ER -